title: Cost-effectiveness of insulin glargine versus sitagliptin in insulin-naïve patients with type 2 diabetes mellitus.
abstract: OBJECTIVE
  In the EASIE (Evaluation of Insulin Glargine Versus Sitagliptin in Insulin-Naïve Patients) trial, insulin glargine found a significant reduction in glycosylated hemoglobin compared with sitagliptin in patients with type 2 diabetes who are inadequately controlled with metformin. The objective of this study was to assess the cost-effectiveness of insulin glargine compared with sitagliptin in type 2 diabetes patients, from the perspective of the publicly funded Canadian health care system.
  
  
  METHODS
  The IMS CORE Diabetes Model, a standard Markov structure and Monte Carlo simulation model, was used. The model used a lifetime horizon to capture the long-term complications associated with type 2 diabetes. The efficacy of insulin glargine and sitagliptin in terms of glycosylated hemoglobin reduction and corresponding rates of hypoglycemia were obtained from the EASIE trial. Health utility and cost data were obtained from recently published Canadian publications. Univariate and probabilistic sensitivity analyses were conducted.
  
  
  RESULTS
  In the lifetime base-case analysis, treatment with insulin glargine resulted in cost savings of $1434 CAD in 2012 and a gain of 0.08 quality-adjusted life years per patient. A probabilistic sensitivity analysis found the robustness of the base-case analysis, with 88% probability of insulin glargine being dominant (ie, cost savings and more quality-adjusted life years).
  
  
  CONCLUSIONS
  Insulin glargine is a clinically superior and cost-effective alternative to sitagliptin in patients with type 2 diabetes who are inadequately controlled with metformin.
authors.affiliation: Cornerstone Research Group Inc., Burlington, Ontario, Canada. Electronic address: sbrown@cornerstone-research.com.
authors.forename: Stephen T
authors.initials: ST
authors.lastname: Brown
authors.affiliation: Cornerstone Research Group Inc., Burlington, Ontario, Canada.
authors.forename: Daniel Grima
authors.initials: DG
authors.lastname: Grima
authors.affiliation: Sanofi Canada, Laval, Quebec, Canada.
authors.forename: Luc
authors.initials: L
authors.lastname: Sauriol
mesh_terms: D002170:Canada; D003362:Cost-Benefit Analysis; D048909:Diabetes Complications / Q000517:prevention & control; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007004:Hypoglycemic Agents / Q000191:economics* / Q000627:therapeutic use; D000069036:Insulin Glargine / Q000191:economics* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009313:National Health Programs; D019057:Quality-Adjusted Life Years; D000068900:Sitagliptin Phosphate / Q000191:economics* / Q000627:therapeutic use
chemical_list: D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D000069036:Insulin Glargine; D000068900:Sitagliptin Phosphate
keywords: cost-effectiveness; insulin glargine; sitagliptin; type 2 diabetes